These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

309 related items for PubMed ID: 16061877

  • 1. Prevention of cancer cachexia by a novel nuclear factor {kappa}B inhibitor in prostate cancer.
    Kuroda K, Horiguchi Y, Nakashima J, Kikuchi E, Kanao K, Miyajima A, Ohigashi T, Umezawa K, Murai M.
    Clin Cancer Res; 2005 Aug 01; 11(15):5590-4. PubMed ID: 16061877
    [Abstract] [Full Text] [Related]

  • 2. Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo.
    Matsumoto G, Namekawa J, Muta M, Nakamura T, Bando H, Tohyama K, Toi M, Umezawa K.
    Clin Cancer Res; 2005 Feb 01; 11(3):1287-93. PubMed ID: 15709200
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. DHMEQ, a novel NF-kappaB inhibitor, induces apoptosis and cell-cycle arrest in human hepatoma cells.
    Nishimura D, Ishikawa H, Matsumoto K, Shibata H, Motoyoshi Y, Fukuta M, Kawashimo H, Goto T, Taura N, Ichikawa T, Hamasaki K, Nakao K, Umezawa K, Eguchi K.
    Int J Oncol; 2006 Sep 01; 29(3):713-9. PubMed ID: 16865289
    [Abstract] [Full Text] [Related]

  • 7. Antitumor effects of dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, in human liver cancer cells are mediated through a reactive oxygen species-dependent mechanism.
    Lampiasi N, Azzolina A, D'Alessandro N, Umezawa K, McCubrey JA, Montalto G, Cervello M.
    Mol Pharmacol; 2009 Aug 01; 76(2):290-300. PubMed ID: 19461054
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Control of allograft rejection by applying a novel nuclear factor-kappaB inhibitor, dehydroxymethylepoxyquinomicin.
    Ueki S, Yamashita K, Aoyagi T, Haga S, Suzuki T, Itoh T, Taniguchi M, Shimamura T, Furukawa H, Ozaki M, Umezawa K, Todo S.
    Transplantation; 2006 Dec 27; 82(12):1720-7. PubMed ID: 17198266
    [Abstract] [Full Text] [Related]

  • 10. Effect of a small molecule inhibitor of nuclear factor-kappaB nuclear translocation in a murine model of arthritis and cultured human synovial cells.
    Wakamatsu K, Nanki T, Miyasaka N, Umezawa K, Kubota T.
    Arthritis Res Ther; 2005 Dec 27; 7(6):R1348-59. PubMed ID: 16277688
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of inflammatory cytokine secretion from mouse microglia cells by DHMEQ, an NF-kappaB inhibitor.
    Takatsuna H, Morita S, Nagatsu T, Sawada M, Umezawa K.
    Biomed Pharmacother; 2005 Jul 27; 59(6):318-22. PubMed ID: 15932789
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of macrophage activation and phagocytosis by a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin.
    Suzuki E, Umezawa K.
    Biomed Pharmacother; 2006 Nov 27; 60(9):578-86. PubMed ID: 16978829
    [Abstract] [Full Text] [Related]

  • 13. Potent cytotoxic effect of a novel nuclear factor-kappaB inhibitor dehydroxymethylepoxyquinomicin on human bladder cancer cells producing various cytokines.
    Kodaira K, Kikuchi E, Kosugi M, Horiguchi Y, Matsumoto K, Kanai K, Suzuki E, Miyajima A, Nakagawa K, Tachibana M, Umezawa K, Oya M.
    Urology; 2010 Apr 27; 75(4):805-12. PubMed ID: 20156648
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Antitumor effect of a novel nuclear factor-kappa B activation inhibitor in bladder cancer cells.
    Horiguchi Y, Kuroda K, Nakashima J, Murai M, Umezawa K.
    Expert Rev Anticancer Ther; 2003 Dec 27; 3(6):793-8. PubMed ID: 14686701
    [Abstract] [Full Text] [Related]

  • 17. Effects of a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on growth, apoptosis, gene expression, and chemosensitivity in head and neck squamous cell carcinoma cell lines.
    Ruan HY, Masuda M, Ito A, Umezawa K, Nakashima T, Yasumatsu R, Kuratomi Y, Yamamoto T, Weinstein IB, Komune S.
    Head Neck; 2006 Feb 27; 28(2):158-65. PubMed ID: 16355386
    [Abstract] [Full Text] [Related]

  • 18. In vivo antitumor activity of the NF-kappaB inhibitor dehydroxymethylepoxyquinomicin in a mouse model of adult T-cell leukemia.
    Ohsugi T, Horie R, Kumasaka T, Ishida A, Ishida T, Yamaguchi K, Watanabe T, Umezawa K, Urano T.
    Carcinogenesis; 2005 Aug 27; 26(8):1382-8. PubMed ID: 15831528
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of inflammatory mediator secretion by (-)-DHMEQ in mouse bone marrow-derived macrophages.
    Suzuki E, Sugiyama C, Umezawa K.
    Biomed Pharmacother; 2009 Jun 27; 63(5):351-8. PubMed ID: 18635336
    [Abstract] [Full Text] [Related]

  • 20. Intratumoral injection of oligonucleotides to the NF kappa B binding site inhibits cachexia in a mouse tumor model.
    Kawamura I, Morishita R, Tomita N, Lacey E, Aketa M, Tsujimoto S, Manda T, Tomoi M, Kida I, Higaki J, Kaneda Y, Shimomura K, Ogihara T.
    Gene Ther; 1999 Jan 27; 6(1):91-7. PubMed ID: 10341880
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.